Effect of Patola-Nimbadi Basti in the Management of Psoriasis w.s.r. to Ekakushtha

An Open Label Clinical Non-Randomized Study to Evaluate the Efficacy of Patola-Nimbadi Basti in the Management of Psoriasis w.s.r. to Ekakushtha - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069477

Enrollment

Registered

2024-06-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects presenting with clinical features of Psoriasis. 2. Patients suffering from psoriasis with less than 50% of the body surface involvement. 3. Subjects with chronicity of disease more than 6 months and less than 5 yrs. 4. The patient who is fit for Basti Karma (Basti Yogya).

Exclusion criteria

Exclusion criteria: 1. Patient presenting with clinical features other than psoriasis like generalized skin lesions, herpes simplex, herpes zooster, scabies, acne, urticaria and immunological medicated skin diseases like pemphigus vulgaris, dermatitis herpetiformis, guttate psoriasis, pustular psoriasis, lupus erythematous, psoriatic arthropathy etc. 2. Patient suffering from severe psoriasis with more than 50% of the body surface involvement. 3. Patient with chronicity of disease less than 6 months and above 5 yrs. 4. Subjects of either sex age below 20 years and above 60 years. 5. Patient on medication like corticosteroids, phototherapy, biologics, antidepressant and any other drugs that may have an influence on the outcome of the study . 6. Alcoholics or drug abusers. 7. Systemic Lupus Erythematous and other Auto Immune disorders. 8. Patients having systematic pathologies like cardiac diseases, renal diseases and endocrine disorders. 9. Pregnant and lactating women. 10. Patient who are contra-indicated for Basti Karma (Basti Ayogya).

Design outcomes

Primary

Measure	Time frame
Relieve in the sign and symptoms of PsoriasisTimepoint: 45th day after treatment.	—

Secondary

Measure	Time frame
1. To improve quality of life of patient. 2. Remove the stress factor of Psoriasis patient. Timepoint: At 15th, 30th, 45th day after treatment.	—

Countries

India

Contacts

Public ContactDr Himanshu

Institute for Ayurved Studies and Research Umri Road Sector 08 Kurukshetra Haryana 136118

chairperson.pk@skau.ac.in8950375285

Outcome results